Abstract:In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against programmed death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA-4). In spite of these improvements, some patients do not achieve any benefit from ICI, and inevitably develop resistance to therapy over time. Tumor microenvironment (TME) might influence response to immunotherapy due to its prominent role in the multiple interactions between neoplastic cells and the immune system. Studies investigating lung cancer from the perspective of TME pointed out a complex scenario where tumor angiogenesis, soluble factors, immune suppressive/regulatory elements and cells composing TME itself participate to tumor growth. In this review, we point out the current state of knowledge involving the relationship between tumor cells and the components of TME in NSCLC as well as their interactions with immunotherapy providing an update on novel predictors of benefit from currently employed ICI or new therapeutic targets of investigational agents. In first place, increasing evidence suggests that TME might represent a promising biomarker of sensitivity to ICI, based on the presence of immune-modulating cells, such as Treg, myeloid derived suppressor cells, and tumor associated macrophages, which are known to induce an immunosuppressive environment, poorly responsive to ICI. Consequently, multiple clinical studies have been designed to influence TME towards a pro-immunogenic state and subsequently improve the activity of ICI. Currently, the mostly employed approach relies on the association of “classic” ICI targeting PD-1/PD-L1 and novel agents directed on molecules, such as LAG-3 and TIM-3. To date, some trials have already shown promising results, while a multitude of prospective studies are ongoing, and their results might significantly influence the future approach to cancer immunotherapy.

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies

Immunosuppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Immunosuppressive Strategies that are Mediated by Tumor Cells

Implications for Optimizing Immunotherapy Outcomes

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

Immunologic tumor microenvironment modulators for turning cold tumors hot

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment

Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Managing the TME to improve the efficacy of cancer therapy

Modulation of Tumor Microenvironment for Immunotherapy: Focus on Nanomaterial-Based Strategies

Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates

Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment

Establishment of immune suppression by cancer cells in the tumor microenvironment

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade